Abstract：【Objective】 To investigate the relationship of ADAMTS13 level (von Willebrand factor lytic protease) with disease activity in patients with lupus nephritis (LN).【Methods】 A total of 100 patients with LN admitted to our hospital from October 2018 to December 2020 were selected as the LN group.According to the systemic lupus erythematosus disease activity index (SLEDAI),patients were divided into the basically inactivity group,mild activity group,moderate activity group and severe activity group.While 100 healthy people in the same period were selected as the control group.Clinical data and blood biochemical indexes were collected.The plasma levels of ADAMTS13,von Willebrand factor (VWF),interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) were determined.【Results】 Compared with the control group,the levels of triacylglycerol (TG),low density lipoprotein (LDL-C) and uric acid in the systemic lupus erythematosus group were significantly higher (P<0.05),while apoA-1 were significantly lower (P<0.05).Compared to the control group,the levels of plasma ADAMTS13,red blood cells,white blood cells,platelets,hemoglobin,complement C3,C4,and plasma of LN patients in the basically inactive group,mildly active group,moderately active group,and severely active group decreased gradually; And plasma levels of inflammatory factors IL-6,TNF-α,VWF and VWF/ADAMTS13 increased in the order of the basically inactive group,mildly active group,moderately active group,and severely active group (P<0.05).The levels of plasma ADAMTS13 in patients with LN were negatively correlated with the levels of IL-6,TNF-α,VWF and SLEDAI (r=-0.405,-0.464,-0.465,-0.925,P<0.05).【Conclusion】 The expression of ADAMTS13 in plasma is low in patients with LN,and the change of ADAMTS13 level is of great significance for the evaluation of disease activity in patients with LN.
王小艳, 贺亚峰*. 狼疮性肾炎患者血浆中ADAMTS13水平与疾病活动度的相关性[J]. 医学临床研究, 2023, 40(1): 88-91.
WANG Xiao-yan, HE Ya-feng. Relationship of Plasma ADAMTS13 Level with Disease Activity in Patients with Lupus Nephritis. JOURNAL OF CLINICAL RESEARCH, 2023, 40(1): 88-91.
[1] YAP D Y H,CHAN T M.B cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments[J].Int J Mol Sci,2019,20(24):6231-6234. [2] TEKTONIDOU M G,DASGUPTA A,WARD M M.Risk of end-stage renal disease in patients with lupus nephritis,1971-2015:A systematic review and bayesian meta-analysis[J].Arthritis Rheumatol,2016,68(6):1432-1441. [3] 俞斌峰,王耀敏,徐莹,等.低剂量利妥昔单抗合并血浆输注治疗系统性红斑狼疮继发血栓性微血管病二例报告并文献复习[J].中华肾脏病杂志,2019,35(6):454-455. [4] 衡军锋,严洁,赵益明,等.vWF和ADAMTS13活性对脓毒症患者早期预后评估的意义[J].中国急救医学,2016,36(10):871-875. [5] TAN Y,LUAN Z Q,HAO J B,et al.Plasma ADAMTS13 activity in proliferative lupus nephritis:a large cohort study from China.[J] .Lupus,2018,27(3):389-398. [6] 李慧,孟德钎,刘焱,等.中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值预测狼疮性肾炎疾病活动度的价值研究[J].中国全科医学,2019,22(11):1307-1311. [7] 雷颜瑛,熊钰.重症狼疮性肾炎行血液透析患者不良心理状态及护理研究进展[J].齐鲁护理杂志,2017,23(6):54-56. [8] OBRISC B,SOROBAN B,TUT L,et al.Advances in Lupus Nephritis Pathogenesis:From Bench to Bedside[J].Int J Mol Sci,2021,22(7):3766. [9] GASPAROTTO M,GATTO M,BINDA V,et al.Lupus nephritis:clinical presentations and outcomes in the 21st century[J].Rheumatology (Oxford),2020,59(Suppl 5):39-51. [10] OCAK G,ROEST M,VERHAAR MC,et al.Von Willebrand factor,ADAMTS13 and mortality in dialysis patients[J].BMC Nephrol,2021,22(1):222. [11] 朱国强,杨淑芬,张雪琴,等.原发性膜性肾病患者血管性血友病因子裂解酶13的血浆水平及其临床意义[J].临床肾脏病杂志,2022,22(9):705-711. [12] 权志慧,陈国涛.狼疮肾炎患者血清维生素D与IL-6、TNF-α水平的研究[J].国际泌尿系统杂志,2018,38(3):449-452.
2023, Vol. 40 
